Skip to main content

16-09-2022 | ESMO 2022 | Conference coverage | Video

Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC

share
SHARE

Melissa Johnson provides an overview of the CodeBreaK 200 study pitting sotorasib against docetaxel in patients who have received prior treatment for non-small-cell lung cancer with KRAS G12C mutations (2:59).